Mercer Global Advisors
CNTX icon

Mercer Global Advisors’s Context Therapeutics CNTX Stock Holding History

Mercer Global Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138 Buy
+250
New +$507 ﹤0.01% 5945

Other funds holding CNTX

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Mercer Global Advisors's CNTX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Context Therapeutics (CNTX) in Q2 2026: 250 shares worth $138. The stake represents ﹤0.01% of the portfolio and ranks #5945 among its holdings.

26 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Mercer Global Advisors held 250 shares of Context Therapeutics worth $138 as of Q2 2026.
  • Context Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5945 holding.
  • 26 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.